

## Alfasigma: production plant in Pomezia (Rome)

Today Alfasigma has four production sites in Italy: Alanno in Abruzzo, Pomezia and Sermoneta in Lazio, Trezzano Rosa In Lombardia. Sermoneta is a chemical plant, while the facilities at Alanno, Pomezia and Trezzano produce prescription and over-the-counter drugs. The Pomezia plant employs 500 people, more than half of whom are in production and production-related services.

**History** — The Pomezia plant was founded in 1957 and saw a series of expansions until the 1990s.



**Dimensions** — To maximise efficiency and logistics, the plant is divided into three areas: production and laboratories, warehouse, utilities and services.

- 350,000 m<sup>2</sup> total surface;
- 17,000 m<sup>2</sup> covered area for production and laboratories (46%);
- 12,000 m<sup>2</sup> for centralised, semi-automatic warehouse with 12 pallet places;
- 7,000 m<sup>2</sup> for services and utilities (20%).

**Production capacity** — The site production capacity is:

- over 1 billion doses per year (oral solids, liquids for injectables and oral suspensions, soft-shell gel capsules);
- over 60 million packs, mainly exported to Europe, Asia and North America, Africa and Japan;
- 20% of the production is for export.

**Products and pharmaceutical forms** — Production focuses on various pharmaceutical forms:

- oral solids (granules in sachets, coated and uncoated tablets, capsules);
- sterile liquids and lyophilised products (vials and bottles);
- oral liquids;
- soft-shell gel capsules (new technology).

The products manufactured include Bentelan, Biochetase, Carnitines, Yovis, Nicetile and Eskim.

**News and future developments** — On the 14<sup>th</sup> of September 2021 the *LABIO 4.0 Marino Golinelli* Technological Development Centre in Pomezia was inaugurated, which will enable the company to achieve new goals and innovations for the pharmaceutical industry. The site hosts the new Research & Development laboratories dedicated to pharmaceutical technology and analytical chemistry with an investment of over 17 million euros. This is where all of the site's Research & Development structures will be concentrated. In the same pavilion, a pilot plant is also being built for the production of experimental drugs, to operate in synergy with all Alfasigma technical and scientific functions

**Giuseppe Allocca** is the Corporate Operations & Supply Chain Executive Director. With a degree in Chemistry, he joined Alfasigma in January 2020 after a long experience in Pfizer where he managed manufacturing plants in Italy and abroad.

**Media Relations**

[CorporateCommunication@alfasigma.com](mailto:CorporateCommunication@alfasigma.com)

[www.alfasigma.com](http://www.alfasigma.com)

*Last update, November 2022.*